Clinical Trials

2 studies in Liver injury

1. DILIN's Prospective Study Rochester, MN View Summary
   Close

   DILIN's Prospective Study

   Location:

   Rochester, MN

   Trial status:

   Open for Enrollment

   Why is this study being done?

   Liver injury due to prescription and non-prescription medication use is a medical, scientific and public health problem of increasing frequency and importance in the United States. Indeed, drug-induced liver injury (DILI) is the most important reason for non-approval, withdrawal, limitation in use and clinical monitoring by the Food and Drug Administration (FDA). However, detection of signals for liver injury frequently relies upon the reporting of cases by practitioners to health authorities in post-marketing surveillance. Under-reporting of cases, lack of mandatory reporting systems, and difficulties in establishing a diagnosis make the current system sub-optimal. Moreover, with the growing use of complementary and alternative medications (CAM), there have also been increasing reports of liver toxicity due to various non-prescription herbal, dietary and food additive supplements. Because the manufacturing, dispensing and testing of these products is not regulated, the hepatotoxic potential of these formulations is poorly characterized or completely unknown. The DILIN Prospective Study is a multi-centered epidemiological study designed to gather clinical information and biological specimens on cases of suspected liver injury due to drugs and CAM. The goals of this study are to develop a database of recent DILI cases, identify the clinical, environmental and genetic risk factors that predict DILI, develop standardized instruments and terminology and perform careful longitudinal follow-up of DILI subjects. Biological samples collected will be used in future studies of the mechanisms and genetics of DILI. Patients who are referred to one of the DILIN clinical sites and who, in the opinion of gastroenterologist/hepatologist, experienced a drug-induced liver injury are enrolled. Detailed clinical data and biological specimens are collected. Clinical data will be reviewed by the DILIN Causality Committee and the final determination on whether the subject qualifies as a bona fide DILI case is made by consensus opinion. DILI cases (only) are followed for at least 6 months to derive the longitudinal profile of drug-and CAM-induced liver injury. Detailed clinical data and biological specimens are collected. Patients who satisfy the definition of chronic DILI will be evaluated at 12 months and 24 months thereafter.

   NCT ID:

   NCT00345930

   • Print Summary
   • View study details

   Who can I contact for additional information about this study?

   Rochester: Stephanie Johnson, RN,BSN,CCRC 507-284-9709
                       None Available
   
   
   

2. Drug-Induced Liver Injury (DILN)Network Retrospective Rochester, MN View Summary
   Close

   Drug-Induced Liver Injury (DILN)Network Retrospective

   Location:

   Rochester, MN

   Trial status:

   Open for Enrollment

   Why is this study being done?

   Drug-induced liver injury (DILI) is the single most common reason for regulatory actions concerning drugs, including failure to gain approval for marketing, removal from the market place, and restriction of prescribing indications. DILI is also a significant cause of morbidity and mortality in many patient populations. To stimulate and facilitate research into DILI, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has recently established the Drug-Induced Liver Injury Network (DILIN). One of the initial projects to be conducted by the network is to retrospectively establish a nationwide registry of patients who have suffered severe idiosyncratic liver injury associated with drugs (ILIAD), and to collect, immortalize and store serum, DNA, and lymphocytes from these patients (hereafter referred to as the "ILIAD protocol"). This ILIAD protocol will serve as a resource for subsequent mechanistic investigations of the basis for susceptibility to severe idiosyncratic DILI. The network will initially identify people who have developed jaundice as a result of treatment with valproic acid, isoniazid, phenytoin, combination clavulanic acid / amoxicillin, nitrofurantoin, trimethoprim-sulfamethoxazole, minocycline, and quinolone antibiotics. In the case of valproic acid, eligibility requires a clinical presentation that is severe enough to prompt hospitalization or is associated with significant biochemical liver dysfunction. The specific aims are as follows: 1. Establish and maintain a clinical database of these people that contains relevant clinical data. The target enrollment will be 50-100 individuals with DILI due to each drug. 2. Establish a bank of biological specimens (serum, DNA, and immortalized lymphocytes) prepared from cases and control in the clinical database. 3. Maintain a registry including yearly updated contact information of the subjects enrolled in the clinical database so that it is possible to recontact these individuals at a later date to offer participation in studies which are not part of the current proposal.

   NCT ID:

   NCT00360646

   • Print Summary
   • View study details

   Who can I contact for additional information about this study?

   Rochester: Stephanie Johnson, BSN 507-284-9709
                       John Poterucha, MD 507-7284-4823